Related Experiment Video
Updated: Apr 30, 2026
08:11
Measuring Caenorhabditis elegans Sensitivity to the Acetylcholine Receptor Agonist Levamisole
Published on: June 7, 2022
5.4K
[Myasthenia gravis and acetylcholine]
1Division of Neurology (Ohashi), Department of Medicine, School of Medicine, Toho University.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|May 9, 2014
Summary
Acetylcholine research has led to treatments for myasthenia gravis (MG). Future drugs should target autoimmunity in MG, not just symptoms, to improve patient outcomes.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Context:
- The discovery of acetylcholine in 1914 revolutionized neuroscience.
- Myasthenia gravis (MG) is a neuromuscular disease historically treated symptomatically.
- Advances in immunology revealed autoimmune mechanisms in MG.
Purpose:
- To review the evolution of myasthenia gravis (MG) treatment.
- To highlight the shift from symptomatic to immunomodulatory therapies.
- To propose future directions for MG drug development.
Summary:
- Early MG treatment involved acetylcholine esterase inhibitors, offering symptomatic relief.
- Current treatments focus on immunosuppression or immunomodulation due to autoimmune attacks on acetylcholine receptors.
- These approaches remain symptomatic and carry risks like immunodeficiency.
Impact:
- Understanding MG's autoimmune basis has led to new therapeutic strategies.
- There is a critical need for treatments that specifically cancel autoimmunity in MG.
- Future drug development should prioritize targeting the root cause of MG for improved efficacy and safety.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:26Chemical Synapses
9.5K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.5K
01:26Chemical Synapses
10.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.9K
01:15Myasthenia Gravis: Diagnostic Tests
3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
01:10Muscle Contraction
6.8K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.8K